194 related articles for article (PubMed ID: 37079030)
21. Establishment and prospective validation of an SUV
Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
[No Abstract] [Full Text] [Related]
22.
Pizzuto DA; Triumbari EKA; Morland D; Boldrini L; Gatta R; Treglia G; Bientinesi R; De Summa M; De Risi M; Caldarella C; Scarciglia E; Totaro A; Annunziata S
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012384
[TBL] [Abstract][Full Text] [Related]
23. Clinical parameters and nomograms for predicting lymph node metastasis detected with
Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer.
Giovacchini G; Giovannini E; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Conti E; Picchio M; Ciarmiello A
Nucl Med Commun; 2019 Mar; 40(3):258-263. PubMed ID: 30507748
[TBL] [Abstract][Full Text] [Related]
25. Is 11C-choline Positron Emission Tomography/Computed Tomography Accurate to Detect Nodal Relapses of Prostate Cancer After Biochemical Recurrence? A Multicentric Study Based on Pathologic Confirmation from Salvage Lymphadenectomy.
Oderda M; Joniau S; Palazzetti A; Falcone M; Melloni G; Van Den Bossche H; Deconinck S; Zattoni F; Karnes RJ; Gontero P
Eur Urol Focus; 2018 Mar; 4(2):288-293. PubMed ID: 30205893
[TBL] [Abstract][Full Text] [Related]
26. Diagnostic Performance and Clinical Impact of
Cerci JJ; Fanti S; Lobato EE; Kunikowska J; Alonso O; Medina S; Novruzov F; Lengana T; Granados C; Kumar R; Rangarajan V; Al-Ibraheem A; Hourani M; Ali NS; Ahmad A; Keidar Z; Küçük O; Elboga U; Bogoni M; Paez D
J Nucl Med; 2022 Feb; 63(2):240-247. PubMed ID: 34215674
[TBL] [Abstract][Full Text] [Related]
27.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and therapeutic impact of PET/CT with 18F-DCFPyL versus 18F-Fluorocholine in initial staging of intermediate-/high-risk prostate cancer: a pilot study.
Lucas Lucas C; García Zoghby L; Amo-Salas M; Soriano Castrejón ÁM; García Vicente AM
Ann Nucl Med; 2023 Oct; 37(10):551-560. PubMed ID: 37532975
[TBL] [Abstract][Full Text] [Related]
29.
Ilhan H; Kroenke M; Wurzer A; Unterrainer M; Heck M; Belka C; Knorr K; Langbein T; Rauscher I; Schmidt-Hegemann NS; Schiller K; Bartenstein P; Wester HJ; Eiber M
J Nucl Med; 2022 Aug; 63(8):1208-1214. PubMed ID: 35273094
[TBL] [Abstract][Full Text] [Related]
30. Robustness of magnetic resonance imaging and positron emission tomography radiomic features in prostate cancer: Impact on recurrence prediction after radiation therapy.
Dutta A; Chan J; Haworth A; Dubowitz DJ; Kneebone A; Reynolds HM
Phys Imaging Radiat Oncol; 2024 Jan; 29():100530. PubMed ID: 38275002
[TBL] [Abstract][Full Text] [Related]
31. Incremental Impact of [
Szigeti F; Schweighofer-Zwink G; Meissnitzer M; Hauser-Kronberger C; Hitzl W; Kunit T; Forstner R; Pirich C; Beheshti M
Mol Imaging Biol; 2022 Feb; 24(1):50-59. PubMed ID: 34519966
[TBL] [Abstract][Full Text] [Related]
32. [Biochemical recurrence after curative treatment for localized prostate cancer: Performance of choline PET/CT in the assessment of local recurrence].
Poncet D; Arnoux V; Descotes JL; Rambeaud JJ; Verry C; Terrier N; Boillot B; Dubreuil J; Lanchon C; Carnicelli D; Fiard G; Long JA
Prog Urol; 2015 May; 25(6):325-30. PubMed ID: 25748788
[TBL] [Abstract][Full Text] [Related]
33. "Real-world" evaluation of
Niziers V; Boissier R; Borchiellini D; Deville JL; Khoury C; Durand M; Toledano H; Albert T; Branger N; Bandelier Q; Ouvrier MJ; Gabriel S; Hoch B; Gross E; Walz J; Brenot-Rossi I; Pignot G
Urol Oncol; 2020 Jan; 38(1):2.e1-2.e9. PubMed ID: 31447087
[TBL] [Abstract][Full Text] [Related]
34. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
35. Application of 18 F-fluorodeoxyglucose PET/CT radiomic features and machine learning to predict early recurrence of non-small cell lung cancer after curative-intent therapy.
Park SB; Kim KU; Park YW; Hwang JH; Lim CH
Nucl Med Commun; 2023 Feb; 44(2):161-168. PubMed ID: 36458424
[TBL] [Abstract][Full Text] [Related]
36. PSMA uptake on [68Ga]-PSMA-11-PET/CT positively correlates with prostate cancer aggressiveness.
Chen M; Qiu X; Zhang Q; Zhang C; Zhou YH; Zhao X; Fu Y; Wang F; Guo H
Q J Nucl Med Mol Imaging; 2022 Mar; 66(1):67-73. PubMed ID: 31359744
[TBL] [Abstract][Full Text] [Related]
37.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
38. Radiomic features from pretreatment biparametric MRI predict prostate cancer biochemical recurrence: Preliminary findings.
Shiradkar R; Ghose S; Jambor I; Taimen P; Ettala O; Purysko AS; Madabhushi A
J Magn Reson Imaging; 2018 Dec; 48(6):1626-1636. PubMed ID: 29734484
[TBL] [Abstract][Full Text] [Related]
39. Gallium-68-prostate-specific membrane antigen (
van Leeuwen PJ; Donswijk M; Nandurkar R; Stricker P; Ho B; Heijmink S; Wit EMK; Tillier C; van Muilenkom E; Nguyen Q; van der Poel HG; Emmett L
BJU Int; 2019 Jul; 124(1):62-68. PubMed ID: 30074667
[TBL] [Abstract][Full Text] [Related]
40. Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging.
Ma TM; Gafita A; Shabsovich D; Juarez J; Grogan TR; Thin P; Armstrong W; Sonni I; Nguyen K; Lok V; Reiter RE; Rettig MB; Steinberg ML; Kupelian PA; Yang DD; Muralidhar V; Chu C; Feng F; Savjani R; Deng J; Parikh NR; Nickols NG; Elashoff D; Czernin J; Calais J; Kishan AU
Eur Urol Oncol; 2022 Feb; 5(1):100-103. PubMed ID: 33602654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]